Stay updated with breaking news from Platinum Sensitive. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer.
Expert oncologists Laurent Greiller, MD, and Christian Grohé, MD, reflect on the current state of second-line treatment options for patients with small cell lung cancer.
Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy.